World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
50887
World Ranking
13386
National Ranking
6808

Overview

Michael Boyer is affiliated with the University of Utah in the United States. Their research spans primarily the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a focus on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology, and Cancer Research.

The main topics of Boyer's work include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer therapeutics and mechanisms
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies

Boyer has a substantial publication record, including contributions to frequent publication venues such as:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts

Some of the recent papers by Boyer are:

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer, 2020, Journal of Clinical Oncology
  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189, 2021, Annals of Oncology
  • The James Webb Space Telescope Mission, 2023, Publications of the Astronomical Society of the Pacific
  • Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC, 2021, Journal of Thoracic Oncology
  • Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial, 2022, Journal of Clinical Oncology

Boyer frequently collaborates with several researchers, including:

  • Enriqueta Felip
  • Jenny Lee
  • Steven Kao
  • Shirish M. Gadgeel
  • Delvys Rodríguez-Abreu

Best Publications

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    S. L. Maude;Theodore W Laetsch;J. Buechner;S. Rives

  • Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne

  • Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

    Nicholas J. Vogelzang;James J. Rusthoven;James Symanowski;Claude Denham

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

    Jean Klastersky;Marianne Paesmans;Edward B. Rubenstein;Michael Boyer

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

    Eric Van Cutsem;Chris Twelves;Jim Cassidy;David Allman

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • The dynamics of change: Cancer patients' preferences for information, involvement and support

    P. N. Butow;M. Maclean;S. M. Dunn;M. H. N. Tattersall

  • First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

    J. Cassidy;C. Twelves;E. Van Cutsem;P. Hoff

  • Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

    Nico van Zandwijk;Nick Pavlakis;Steven C Kao;Anthony Linton

  • Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

    Elena J. Orlando;Xia Han;Catherine Tribouley;Patricia A. Wood

  • Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

    L. Paz-Ares;E. H. Tan;K. O'Byrne;L. Zhang

  • Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

    Suresh S. Ramalingam;Fiona Blackhall;Maciej Krzakowski;Carlos H. Barrios

  • Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

    J von Pawel;R von Roemeling;U Gatzemeier;M Boyer

  • High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy

    Steven C.H. Kao;Nick Pavlakis;Rozelle Harvie;Janette L. Vardy

  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

    Robert J. Soiffer;Haesook T. Kim;Joseph McGuirk;Mitchell E. Horwitz

  • The M ultinational A ssociation f or S upportive C are i n Cancer R isk I ndex: A M ultinational S coring S ystem f or Identifying L ow-Risk F ebrile N eutropenic C ancer P atients

    Jean Klastersky;Marianne Paesmans;Edward B. Rubenstein;Michael Boyer

Frequent Co-Authors

Stephen J. Clarke
Stephen J. Clarke University of Sydney
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Tony Mok
Tony Mok Chinese University of Hong Kong
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Michael A. Pulsipher
Michael A. Pulsipher University of Utah
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Edward B. Garon
Edward B. Garon University of California, Los Angeles
Martin H.N. Tattersall
Martin H.N. Tattersall University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up many paths beyond the traditional MD route. For those interested in leadership or administration, a healthcare administration degree online accredited program offers flexibility and specialized training for managing healthcare organizations. These accredited online degrees allow students to balance their studies with professional or personal obligations.

Aspiring nurse practitioners may consider asn to fnp programs. These bridge programs are designed for registered nurses who want to advance their clinical knowledge and become Family Nurse Practitioners, opening doors to higher-level patient care roles.

Nutrition is another essential part of healthcare. An increasing number of students are enrolling in online nutrition degree programs to gain the expertise needed for clinical, public health, and wellness careers.

For those seeking advanced administrative or executive roles, cahme accredited online healthcare administration programs provide a rigorous, industry-recognized curriculum entirely online. These diverse degree options expand opportunities for anyone passionate about healthcare, whether in direct patient care, management, or allied fields.

Best Scientists Citing Michael Boyer

Trending Scientists